Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | RARB | P10826 | 6/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | RARA | P10276 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2494105 | 0.91 | ANPEP (0.46) | ALDH1A1RARBTSHRTP53KMT2A | |
| SCHEMBL15569203 | 0.82 | ALDH1A1 (0.44) | ALDH1A1RARBTSHRTP53KMT2A | |
| SCHEMBL3484851 | 0.80 | RARB (0.42) | ALDH1A1RARBTSHRKMT2AMEN1 | |
| SCHEMBL2160715 | 0.80 | CYP4A11 (0.57) | ALDH1A1TP53KMT2AMEN1MAPT | |
| SCHEMBL9414680 | 0.79 | MMP12 (0.54) | ALDH1A1RARBTSHRTP53KMT2A | |
| SCHEMBL7266310 | 0.78 | ACE (0.47) | ALDH1A1TSHRKMT2AMEN1HTT | |
| SCHEMBL70166 | 0.77 | TSHR (0.67) | ALDH1A1RARBTSHRTP53KMT2A | |
| Terephthalic Acid SCHEMBL4612225 | 0.77 | TSHR (0.67) | ALDH1A1RARBTSHRTP53KMT2A | |
| SCHEMBL104594 | 0.77 | GRIN2D (0.57) | ALDH1A1RARBTSHRTP53KMT2A | |
| SCHEMBL3484853 | 0.76 | RXRA (0.43) | ALDH1A1RARBKMT2AMEN1RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142495-B1 | SUBSTITUTED DIBENZOIC ACID DERIVATIVES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-04-27 | — | — | EP | disclosed |
| US-8217063-B2 | Lactam-substituted dicarboxylic acids and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-07-10 | — | — | US | disclosed |
| EP-2142504-B1 | LACTAM-SUBSTITUTED DICARBOXYLIC ACIDS AND USE THEREOF | Bayer Pharma AG (DE) | 2011-10-26 | — | — | EP | disclosed |
| US-7985876-B2 | Substituted dibenzoic acid derivatives and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-26 | — | — | US | disclosed |
| US-20100197680-A1 | LACTAM-SUBSTITUTED DICARBOXYLIC ACIDS AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-05 | — | — | US | disclosed |
| US-20100168240-A1 | SUBSTITUTED DIBENZOIC ACID DERIVATIVES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-01 | — | — | US | disclosed |
| EP-2142495-A1 | SUBSTITUTED DIBENZOIC ACID DERIVATIVES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-01-13 | — | — | EP | disclosed |
| EP-2142504-A2 | LACTAM-SUBSTITUTED DICARBOXYLIC ACIDS AND USE THEREOF | Bayer Schering Pharma AG (DE) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119457-A2 | LACTAM-SUBSTITUTED DICARBOXYLIC ACIDS AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008119458-A1 | SUBSTITUTED DIBENZOIC ACID DERIVATIVES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168240-A1 | SUBSTITUTED DIBENZOIC ACID DERIVATIVES AND USE THEREOF | BBOX1, DDC, DDT | ALDH1A1 27/4885RARB 339/4885TSHR 3268/4885 |
| US-20100197680-A1 | LACTAM-SUBSTITUTED DICARBOXYLIC ACIDS AND USE THEREOF | DDO, DDC, BCAT2 | ALDH1A1 1142/4885RARB 3401/4885TSHR 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.